½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1244173

¼¼°èÀÇ °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå(2023-2031³â) : ¼ºÀå, Àü¸Á, °æÀï ºÐ¼®

Oral Thin Film Drugs Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Acute Market Reports | ÆäÀÌÁö Á¤º¸: ¿µ¹® 116 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2031³â±îÁö 9.21%ÀÇ CAGR·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2030³â 62¾ï 7,470¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°æ±¸ ¹Ú¸· Á¦Á¦Àº ü³»¿¡¼­ ¿ëÇصDZ⠽±±â ¶§¹®¿¡ ÀαⰡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Áúº´ ¿ëÇؼº ¾àÁ¦¸¦ ¹ß°ßÇϱâ À§ÇØ ±â¾÷Àº R&D ÅõÀÚ¸¦ Áõ°¡½ÃÅ°°í ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ °æ±¸ ¹Ú¸· Á¦Á¦(Oral Thin Film Drugs) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç ½ÃÀå ÁÖ¿ä ¿ä¾à, ½ÃÀå ¼ºÀå °¢Á¾ ¿µÇâ ¿äÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ, ¿¹Ãø, °¢Á¾ ±¸ºÐ, Áö¿ªº° ³»¿ª, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÇÊ µîÀ» Á¤¸®ÇÏ¿© ÀüÇص帳´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå : °æÀï ºÐ¼®

  • ÁÖ¿ä º¥´õ ½ÃÀå Æ÷Áö¼Å´×
  • º¥´õ ä¿ë Àü·«
  • ÁÖ¿ä »ê¾÷ Àü·«
  • Ƽ¾î ºÐ¼®

Á¦4Àå °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå : ¸ÅÅ©·Î ºÐ¼®, ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ÃËÁø ¿äÀÎ
    • ½ÃÀå ¾ïÁ¦ ¿äÀÎ
    • ÁÖ¿ä °úÁ¦
    • ÁÖ¿ä ±âȸ
  • ÃËÁø ¿äÀÎ, ¾ïÁ¦ ¿äÀÎ ¿µÇ⠺м®
  • ½Ã¼Ò ºÐ¼®
  • Æ÷ÅÍÀÇ 5°¡Áö °æÀï ¿äÀÎ ¸ðÇü
  • PESTEL ºÐ¼®
  • Heptalysis ºÐ¼®
  • ±Ùº» ¿øÀÎ ºÐ¼® : »ç¾÷»ó °úÁ¦ Áß¿ä Á¶»ç¿Í °ü·Ã ¼Ö·ç¼Ç

Á¦5Àå °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå : Á¦Ç°º°

  • ½ÃÀå ÁÖ¿ä ¿ä¾à
  • ¼ºÀå, ¼öÀÍ ºÐ¼®
  • ½ÃÀå ºÐ·ù
    • ¼³ÇÏ Çʸ§
    • ¿ÏÀü ¿ëÇØ ¹èÄ® Çʸ§

Á¦6Àå °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå : ÀûÀÀÁõº°

  • ½ÃÀå ÁÖ¿ä ¿ä¾à
  • ¼ºÀå, ¼öÀÍ ºÐ¼®
  • ½ÃÀå ºÐ·ù
    • ÆíµÎÅë
    • Á¤½ÅºÐ¿­Áõ
    • ¾ËÃ÷ÇÏÀ̸Ӻ´
    • ¸Þ½º²¨¿ò, ±¸Åä
    • ¿ÀÇÇ¿ÀÀ̵å ÀÇÁ¸Áõ °Ë»ç
    • ±âŸ

Á¦7Àå Áö¿ª ºÐ¼®

  • ½ÃÀå ÁÖ¿ä ¿ä¾à
  • ¸ÅÅ©·Î ¿äÀÎ, ½ÃÀå ¿µÇâ
  • Æ÷ÅÍÀÇ 5°¡Áö °æÀï ¿äÀÎ ¸ðÇü
  • PESTEL ÀÎÀÚ ¿µÇâ

Á¦8Àå ºÏ¹Ì °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå

Á¦9Àå ¿µ±¹ ¹× EU °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾ç °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå

Á¦11Àå ¶óƾ¾Æ¸Þ¸®Ä« °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå

Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« °æ±¸ ¹Ú¸· Á¦Á¦ ½ÃÀå

Á¦13Àå ±â¾÷ ÇÁ·ÎÇÊ

  • Esteive Therapeutics
  • Tesa Labtec Gmbh
  • Pfizer Inc
  • Novartis AG
  • Wolters Kluwer
  • Solvay
  • Allergan Plc
  • Sumitomo Dainippon Pharma Co. Ltd
  • Intelgenx Corp
  • OPKO Health
  • ZIM Laboratories Ltd.
  • NAL Pharma
  • CURE Pharmaceutical
  • Kyu Kyu Pharmaceutical Co., Ltd.
  • CLPharm Co., Ltd.
  • ±âŸ
NJH 23.03.31

The market for oral thin film drugs is expected to reach US $6274.7 Million by 2030 registering a CAGR of 9.21% during the period forecast of 2023 to 2031. Oral thin films are drug delivery dosage device that is made up of a mono-polymeric thin film that is deposited in the mouth for a fast release of an active pharmaceutical ingredient (API) when placed on the tongue. The absorbed medicinal chemicals are then sent straight into the circulatory system. The popularity of oral thin film (OTF) medications can be attributed to the ease with which they are dissolved in the body. The increasing proportion of elderly people in the community has increased the demand for innovative approaches to the administration of drugs to treat and prevent chronic conditions such as diabetes. The growth of the market for oral thin film pharmaceuticals is anticipated to be helped along by an increase in the amount of money that businesses invest in research and development (R&D) to discover soluble treatments for a variety of diseases. When introduced in less developed nations, OTF medications have the potential to increase revenue for the market.

The rising incidence of Parkinson's disease is expected to stimulate consumer demand for OTFs

The increasing prevalence of target diseases as well as the benefits that come with using thin films is boosting the market for OTFs. For example, the Parkinson's Foundation 2021 estimated that more than 10.0 million people were living with Parkinson's disease around the world. According to another finding from the same survey, there were approximately one million people in the United States living with Parkinson's disease in the year 2021. Also, the probability of developing Parkinson's disease rises with age; as a result, the growing elderly population around the world is anticipated to have a beneficial impact on the market. In addition, a report published by the Parkinson's Foundation in 2021 projects that there will be an additional 1.2 million people affected with Parkinson's disease by the year 2030. This projection is based on current trends. It is generally agreed that oral thins are among the more successful therapies for Parkinson's disease. As a result, the rising incidence of Parkinson's disease is expected to stimulate consumer demand for oral thins, which will, in turn, drive the expansion of the market.

Growth in investment in R&D of fast-dissolving oral films driving oral thin films market statistics

An oral film that dissolves quickly is the most recent and technologically advanced form of an oral solid dose. It provides increased versatility as well as comfort. Oral films that dissolve quickly improve the efficiency of APIs since they do not require chewing to dissolve in the oral cavity within minutes of coming into touch with saliva. Oral films also do not require the use of water during the administration process. Because of the strong blood flow and the ability of the oral mucosa to absorb substances, these medications are absorbed rapidly and have an immediate effect on the body. Because of these advantages, it is anticipated that the oral thin films business will experience growth over the next few years.

Key Opportunities

The opportunity for the OTF market is in the expansion in the global sector that has been fuelled by a high level of tolerance, in addition to great benefits. The growth of the oral thin film market has been fuelled, in part, by the increased investment of major players in research and development (R&D). To strengthen their positions in the oral thin film market, major companies in this market are concentrating their efforts on the development of quickly dissolving oral thin films by employing novel platform technologies such as soul leaves, XGEL, and waferTab.

Sublingual Film Products Dominating the Market

According to the most recent findings of an in-depth study on the oral thin films market, the sublingual film product segment held a substantial proportion in the year 2022. The sublingual mucosa has a high level of vascularization, which, along with the thin membrane structure, results in a high level of membrane permeability. The bioavailability of the sublingual mucosa is exceptionally high. Better permeability can be attributed to higher blood flow and lymphatic circulation, which circumvents the first-pass effect and leads to increased systemic bioavailability. Both of these factors contribute to the body's ability to absorb a substance.

Neuro Segment to Dominate the Market by Indication

During the projected period, it is anticipated that the neurological segment disorders indication segment will have the largest share of the oral thin films market. The increased frequency of neurological illnesses around the world is one factor that can be attributed to the growth of this sector. In the European Union, neurological illnesses constitute the third most common reason for both disability and death in people under the age of 65. Therapies that need quick drug absorption, such as those for pain, allergies, sleep disorders, and disorders of the nervous system, are well suited for administration via oral thin films.

North America to Remain as the Global Leader

The market for oral thin film medicines will be further propelled forward in the future by factors such as the growing demand for effective drug delivery routes and the acceptance of these routes in the region. North America is expected to continue its dominance concerning market revenues across the forecast period.  In addition, a study that was published in the journal of the Migraine Research Foundation in September 2022 found that more than 39 million people in the United States suffer from migraines on an annual basis, with women being three times more likely than males to be affected by the condition. On the other hand, favorable regulations, rising levels of knowledge among the general population, and the introduction of innovative products would cause the Asia Pacific to be the geographical region with the most rapid expansion throughout the projected period. The market for thin oral thin film pharmaceuticals is expected to profit further from the growing target population in the region, as well as the significant contributions made by India and China to the advancement of pharmaceutical technology.

Market to Offer Significant Opportunities to Major Players During the Forecast Period

The major companies in the market have increased investment significantly in research and development (R&D), which has been a driving force behind the market's expansion towards oral thin films. Companies of significant size that are active in the market for oral thin films are concentrating their efforts on making investments in the research and development of fast-dissolving oral thin films. This is done to bolster their position in the market through the implementation of new platform technologies such as soul leaves, XGEL, and waferTab. Research and development contribute to the creation of novel solutions that have the potential to be more practical, productive, and economical in the delivery of drugs.

Acquestive and Cure Pharmaceutical remain the dominant players that are comparatively active and have strong market presence. Companies such as IntelGen corp are expected to witness significant opportunities during the forecast period. Sumitomo Diaippon and CL pharm are emerging players and are not very active as dominant market players. Tesa and Zim are expected to join the tier 1 market player club during the forecast period.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Oral Thin Film Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Oral Thin Film Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Product

Sublingual Film

Fully Dissolving Buccal Film

Indication

Migrainet

Schizophrenia

Alzheimer's Disease

Nausea & Vomiting

Opioid Dependence Tests

Other Indication

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Oral Thin Film Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Oral Thin Film Drugs market?

Which is the largest regional market for Oral Thin Film Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Oral Thin Film Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Oral Thin Film Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Oral Thin Film Drugs Market
  • 2.2. Global Oral Thin Film Drugs Market, By Product, 2022 (US$ Million)
  • 2.3. Global Oral Thin Film Drugs Market, By Indication, 2022 (US$ Million)
  • 2.4. Global Oral Thin Film Drugs Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022
  • 2.6. Key Buying Criteria
  • 2.7. Key Case Reports
  • 2.8. Scenario Analysis
    • 2.8.1. Optimistic estimates and analysis
    • 2.8.2. Realistic estimates and analysis
    • 2.8.3. Pessimistic estimates and analysis
  • 2.9. Market Profiling
  • 2.10. Sales and Marketing Plan
  • 2.11. Top Market Conclusions
  • 2.12. Strategic Recommendations

3. Oral Thin Film Drugs Market: Competitive Analysis

  • 3.1. Market Positioning of Key Oral Thin Film Drugs Market Vendors
  • 3.2. Strategies Adopted by Oral Thin Film Drugs Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Oral Thin Film Drugs Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Oral Thin Film Drugs Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape
  • 4.8. Heptalysis Analysis
  • 4.9. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions

5. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Sublingual Film
    • 5.3.2. Fully Dissolving Buccal Film

6. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Migrainet
    • 6.3.2. Schizophrenia
    • 6.3.3. Alzheimer's Disease
    • 6.3.4. Nausea & Vomiting
    • 6.3.5. Opioid Dependence Tests
    • 6.3.6. Other Indication

7. Geographic Analysis

  • 7.1. Market Overview
  • 7.2.Macro Factors versus Market Impact: Dashboard, 2022
  • 7.3. Porters Five Force Model Across Geography: Dashboard, 2022
  • 7.4. Impact of PESTEL factors Across Geography: Dashboard, 2022

8. North America Oral Thin Film Drugs Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
  • 8.3. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
  • 8.4.Oral Thin Film Drugs Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.North America
      • 8.4.1.1. U.S.
        • 8.4.1.1.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 8.4.1.1.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 8.4.1.2. Canada
        • 8.4.1.2.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 8.4.1.2.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 8.4.1.3. Rest of North America
        • 8.4.1.3.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 8.4.1.3.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)

9. UK and European Union Oral Thin Film Drugs Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
  • 9.3. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
  • 9.4.Oral Thin Film Drugs Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.UK and European Union
      • 9.4.1.1. UK
        • 9.4.1.1.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 9.4.1.1.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 9.4.1.2. Germany
        • 9.4.1.2.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 9.4.1.2.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 9.4.1.3. Spain
        • 9.4.1.3.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 9.4.1.3.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 9.4.1.4. Italy
        • 9.4.1.4.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 9.4.1.4.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 9.4.1.5. France
        • 9.4.1.5.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 9.4.1.5.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Europe
        • 9.4.1.6.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 9.4.1.6.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)

10. Asia Pacific Oral Thin Film Drugs Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
  • 10.3. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
  • 10.4.Oral Thin Film Drugs Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Asia Pacific
      • 10.4.1.1. China
        • 10.4.1.1.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 10.4.1.1.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 10.4.1.2. Japan
        • 10.4.1.2.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 10.4.1.2.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 10.4.1.3. India
        • 10.4.1.3.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 10.4.1.3.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 10.4.1.4. Australia
        • 10.4.1.4.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 10.4.1.4.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 10.4.1.5. South Korea
        • 10.4.1.5.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 10.4.1.5.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 10.4.1.6. Rest of Asia Pacific
        • 10.4.1.6.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 10.4.1.6.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)

11. Latin America Oral Thin Film Drugs Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
  • 11.3. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
  • 11.4.Oral Thin Film Drugs Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Latin America
      • 11.4.1.1. Brazil
        • 11.4.1.1.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 11.4.1.1.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 11.4.1.2. Mexico
        • 11.4.1.2.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 11.4.1.2.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Latin America
        • 11.4.1.3.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 11.4.1.3.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)

12. Middle East and Africa Oral Thin Film Drugs Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
  • 12.3. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
  • 12.4.Oral Thin Film Drugs Market: By Region, 2021-2031, USD (Million)
    • 12.4.1.Middle East and Africa
      • 12.4.1.1. GCC
        • 12.4.1.1.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 12.4.1.1.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 12.4.1.2. Africa
        • 12.4.1.2.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 12.4.1.2.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)
      • 12.4.1.3. Rest of Middle East and Africa
        • 12.4.1.3.1. Oral Thin Film Drugs Market: By Product, 2021-2031, USD (Million)
        • 12.4.1.3.2. Oral Thin Film Drugs Market: By Indication, 2021-2031, USD (Million)

13. Company Profile

  • 13.1. Aquestive Therapeutics
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Tesa Labtec Gmbh
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Pfizer Inc
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Novartis AG
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Wolters Kluwer
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Solvay
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. Allergan Plc
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. Sumitomo Dainippon Pharma Co. Ltd
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. Intelgenx Corp
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. OPKO Health
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. ZIM Laboratories Ltd.
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. NAL Pharma
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
  • 13.13. CURE Pharmaceutical
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Initiatives
  • 13.14. Kyu Kyu Pharmaceutical Co., Ltd.
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Portfolio
    • 13.14.4. Strategic Initiatives
  • 13.15. C.L.Pharm Co., Ltd.
    • 13.15.1. Company Overview
    • 13.15.2. Financial Performance
    • 13.15.3. Product Portfolio
    • 13.15.4. Strategic Initiatives
  • 13.16. Others
    • 13.16.1. Company Overview
    • 13.16.2. Financial Performance
    • 13.16.3. Product Portfolio
    • 13.16.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦